Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 March 2025 – European Medicines Agency |

1. Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 March 2025  European Medicines Agency |
2. Eli Lilly Alzheimer’s Drug Kisunla Fails to Get EU Backing  Mint
3. Lilly’s statement about the CHMP opinion issued for donanemab  Investors | Eli Lilly and Company
4. Lilly stock dips as Kisunla misses EU approval  Investing.com India
5. Eli Lilly’s Alzheimer’s drug rejected in Europe  Reuters

 Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 March 2025  European Medicines Agency |Eli Lilly Alzheimer’s Drug Kisunla Fails to Get EU Backing  MintLilly’s statement about the CHMP opinion issued for donanemab  Investors | Eli Lilly and CompanyLilly stock dips as Kisunla misses EU approval  Investing.com IndiaEli Lilly’s Alzheimer’s drug rejected in Europe  Reuters  Top stories – Google News